5
Novelix Pharmaceuticals
TRIMURTHILTD NSE
Novelix Pharmaceuticals
RetailNSE: TRIMURTHILTD BSE: 536565 Pharmacy Retail
Key Fundamentals
MicrocapPharmacy RetailRetailMarket Cap
₹212 Cr
Volatility
Moderate
P/E Ratio
59.1
EBITDA
₹-2.00 Cr
Return on Equity
-26.4%
Debt to Equity
0.09
Book Value
₹23.08
52W High
₹92
52W Low
₹38
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
5- Company is almost debt free.
- Company is expected to give good quarter
- Promoter holding has increased by 4.86% over last quarter.
- Company's median sales growth is 42.1% of last 10 years
- Company's working capital requirements have reduced from 222 days to 122 days
Weaknesses
5- Stock is trading at 3.51 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 5.12% over last 3 years.
- Company has high debtors of 163 days.
- Promoter holding has decreased over last 3 years: -12.6%
Growth Rate
Revenue Growth
-4.17% lower than
3Y
Net Income Growth
-47.37% lower than
3Y
Cash Flow Change
0% lower than
3Y
ROE
-48.34% lower than
3Y
ROCE
-47.7%
EBITDA Margin (Avg.)
317%
Quarterly Results
| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1.95 | 0.93 | 0.5 | 0.84 | 0.6 | 3.96 | 5.3 | 20.86 | 22.35 | 36.36 | 48.4 | 25.19 | 36.91 |
| Expenses | 2.14 | 1.04 | 0.61 | 0.69 | 1.04 | 3.74 | 5.17 | 20.63 | 22.17 | 35.66 | 47.09 | 23.91 | 35.6 |
| Operating Profit | -0.19 | -0.11 | -0.11 | 0.15 | -0.44 | 0.22 | 0.13 | 0.23 | 0.18 | 0.7 | 1.31 | 1.28 | 1.31 |
| OPM % | -9.74% | -11.83% | -22% | 17.86% | -73.33% | 5.56% | 2.45% | 1.1% | 0.81% | 1.93% | 2.71% | 5.08% | 3.55% |
| Other Income | 0.05 | 0.05 | 0.09 | 0.13 | 0.1 | -0.08 | 0 | 0 | 0 | 0.03 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.12 |
| Depreciation | 0.01 | 0.01 | 0.01 | 0.01 | 0 | 0 | 0 | 0.02 | 0.01 | 0.01 | 0.03 | 0.05 | 0.07 |
| PBT | -0.15 | -0.07 | -0.03 | 0.27 | -0.34 | 0.14 | 0.13 | 0.21 | 0.17 | 0.72 | 1.28 | 1.23 | 1.12 |
| Tax % | 6.67% | 0% | 0% | 0% | 2.94% | 0% | -15.38% | 14.29% | 41.18% | 26.39% | 21.88% | 26.02% | -5.36% |
| Net Profit | -0.17 | -0.07 | -0.03 | 0.28 | -0.35 | 0.13 | 0.15 | 0.18 | 0.11 | 0.53 | 1 | 0.91 | 1.18 |
| EPS in Rs | -0.21 | -0.09 | -0.04 | 0.35 | -0.35 | 0.13 | 0.15 | 0.18 | 0.09 | 0.37 | 0.58 | 0.43 | 0.49 |
Profit & Loss
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1 | 1 | 4 | 3 | 4 | 2 | 1 | 1 | 2 | 4 | 31 | 132 | 147 |
| Expenses | 1 | 1 | 3 | 3 | 3 | 1 | 4 | 3 | 2 | 4 | 31 | 129 | 142 |
| Operating Profit | 0 | 0 | 0 | 0 | 0 | 0 | -3 | -2 | 0 | 0 | 0 | 3 | 5 |
| OPM % | 33% | 43% | 5% | 15% | 6% | 12% | -244% | -151% | 0% | -6% | 0.5% | 2.6% | 3.1% |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| PBT | 0 | 0 | 0 | 0 | 0 | 0 | -3 | -2 | 0 | 0 | 0 | 3 | 4 |
| Tax % | 88% | 31% | 24% | 34% | -32% | 20% | 0% | -1% | 0% | 50% | 33% | 25% | — |
| Net Profit | 0 | 0 | 0 | 0 | 0 | 0 | -3 | -2 | 0 | 0 | 0 | 3 | 4 |
| EPS in Rs | 0.02 | 0.12 | 0.19 | 0.22 | 0.31 | 0.11 | -4.04 | -1.93 | -0.07 | 0.01 | 0.08 | 1.21 | 1.87 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | — |
Balance Sheet
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 10 | 21 |
| Reserves | 3 | 3 | 3 | 4 | 4 | 4 | 1 | -1 | -1 | -1 | 8 | 25 |
| Borrowings | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 |
| Other Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 10 | 42 |
| Total Liabilities | 12 | 12 | 12 | 12 | 12 | 12 | 9 | 7 | 7 | 7 | 27 | 92 |
| Fixed Assets | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 3 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 1 | 3 | 2 | 3 | 3 | 4 | 4 | 1 | 3 | 3 | 0 | 0 |
| Other Assets | 9 | 8 | 9 | 9 | 9 | 8 | 5 | 5 | 4 | 4 | 27 | 89 |
| Total Assets | 12 | 12 | 12 | 12 | 12 | 12 | 9 | 7 | 7 | 7 | 27 | 92 |
Cash Flow
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 0 | 2 | -1 | 1 | 0 | 1 | 1 | 1 | -2 | 0 | -14 | -22 |
| Investing | 0 | -2 | 1 | -1 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | -2 |
| Financing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 11 | 26 |
| Net Cash Flow | -1 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | -2 | 0 | 1 | 2 |
| Free Cash Flow | -1 | 2 | -1 | 1 | 0 | 1 | 0 | -1 | -2 | 0 | -14 | -26 |
| CFO/OP | -90 | 472 | -535 | 225 | -220 | 672 | -18 | -34 | — | 136 | -9,771 | -643 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 30 | 4 | 40 | 130 | 216 | 19 | 25 | 32 | 36 | 1 | 216 | 163 |
| Inventory Days | 0 | — | 28 | 19 | 13 | 39 | 89 | 239 | 222 | 113 | 10 | 42 |
| Days Payable | — | — | 0 | 54 | 13 | 5 | 4 | 0 | 14 | 0 | 115 | 116 |
| Cash Conversion Cycle | 30 | 4 | 68 | 95 | 216 | 54 | 111 | 271 | 244 | 114 | 111 | 88 |
| Working Capital Days | 2,225 | 2,584 | 863 | 932 | 858 | 1,711 | 819 | 647 | 743 | 346 | 197 | 122 |
| ROCE % | 1% | 1% | 1% | 3% | 1% | 1% | -31% | -19% | -1% | 0% | 1% | 10% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Novelix Pharmaceuticals insights
61 extracted metrics + investor summaries across FY09–FY26.
Documents
1
Intimation Under Regulation 30 (LODR) Regulations, 2015- Website Address.
5 May - Company intimates official website https://novelixpharma.com under Regulation 30/46 compliance. 5 May - Company intimates official website https://novelixpharma.com under Regulation 30/46 compliance.
2
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
28 Apr - Novelix Pharmaceuticals confirms it is not a large corporate as of 31 March 2026. 28 Apr - Novelix Pharmaceuticals confirms it is not a large corporate as of 31 March 2026.
3
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
28 Apr - Novelix Pharmaceuticals confirms it is not a large corporate as of 31 March 2026. 28 Apr - Novelix Pharmaceuticals confirms it is not a large corporate as of 31 March 2026.
4
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
28 Apr - Novelix Pharmaceuticals confirms it is not a large corporate as of 31 March 2026. 28 Apr - Novelix Pharmaceuticals confirms it is not a large corporate as of 31 March 2026.
5
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
9 Apr - Submitted Regulation 74(5) depository certificate for quarter ended 31 March 2026. 9 Apr - Submitted Regulation 74(5) depository certificate for quarter ended 31 March 2026.
3
Shareholders Meeting- Notice Of Annual General Meeting To Be Held On Wednesday 30Th September 2026. 7 Sept 2026
Intimation
Frequently Asked Questions about Novelix Pharmaceuticals
What does Novelix Pharmaceuticals Ltd do?
Incorporated in 1994, Novelix Pharmaceuticals Ltd trades in Pharmaceuticals and related products , shares, and securities[1]
Where is Novelix Pharmaceuticals Ltd (536565) listed?
Novelix Pharmaceuticals Ltd trades as TRIMURTHILTD on the NSE and under code 536565 on the BSE.
Which sector does Novelix Pharmaceuticals Ltd belong to?
Novelix Pharmaceuticals Ltd is classified under the Retail sector, in the Pharmacy Retail industry.
What is the market capitalisation of Novelix Pharmaceuticals Ltd?
Novelix Pharmaceuticals Ltd has a market capitalisation of ₹212.15 Cr, which places it in the Small Cap band.
What is the PE ratio of Novelix Pharmaceuticals Ltd?
Novelix Pharmaceuticals Ltd trades at a PE ratio of 59.10, against a book value of ₹23.08 per share.
What is the 52-week high and low of Novelix Pharmaceuticals Ltd?
Over the last 52 weeks Novelix Pharmaceuticals Ltd has traded between ₹38 and ₹92.
What is the Return on Equity (ROE) of Novelix Pharmaceuticals Ltd?
Novelix Pharmaceuticals Ltd reported a return on equity of -26.40%. Its debt-to-equity ratio is 0.09.
Company Information
Incorporated in 1994, Novelix Pharmaceuticals Ltd trades in Pharmaceuticals and related products , shares, and securities[1]
Website trimurthidrugs.com
Face Value ₹ 10
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/536565.md for Novelix Pharmaceuticals Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.